Quigley sales
This article was originally published in The Tan Sheet
Executive Summary
Cold-Eeze marketer spent $714,329 on cooperative advertising promotions during third quarter ended Sept. 30, more than triple the level spent in the year-ago period, 1Quigley's 10-Q says. Net sales rose 19.2% to $8.3 mil., with a net loss of $500,395, compared to net income of $313,615 in the year-ago period. Quigley is partnering with CDC to include educational materials about appropriate antibiotic use in Cold-Eeze samples sent to 7,000-8,000 healthcare providers by year end. Firm also intends to introduce one Cold-Eeze line extension in March 2003; honey lemon-flavored zinc lozenge, the line's most recent addition, began shipping in August (2"The Tan Sheet" Feb. 25, 2002, In Brief)...
You may also be interested in...
Quigley “eezes” into profitability
Cold-Eeze marketer will add honey lemon flavor to zinc lozenge line in time for next cold season, firm says Feb. 19. All Cold-Eeze products will be promoted in the fall with six-week radio ad campaign; Quigley says it has shifted emphasis from broad-based media campaigns to more "efficient" programs, to which firm attributes recent strong earnings growth. For the year, Quigley reported revenues up 46.8% to $24.7 mil., with net income of $216,000 compared with a $5.2 mil. loss last year. Q4 revenue rose 19.7% to $8.5 mil.; net income inched up 2.7%...
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.
Cochlear’s Osia System Receives Expanded FDA Clearance For Use In Younger Children
Kids ages 5 and up now can benefit from Cochlear’s Osia implant and sound processor, indicated for hearing loss, mixed hearing loss and single-sided sensorineural deafness.